Literature DB >> 4414651

Metabolism of hexamethylmelamine-ring-14C in rats and man.

J F Worzalla, B D Kaiman, B M Johnson, G Ramirez, G T Bryan.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4414651

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  13 in total

Review 1.  New drugs under clinical evaluation in the United States.

Authors:  S K Carter
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

2.  Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activation.

Authors:  C J Rutty; I R Judson; G Abel; P M Goddard; D R Newell; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Pharmacokinetics and metabolism of hexamethylmelamine in mice after IP administration.

Authors:  J Dubois; G Atassi; M Hanocq; F Abikhalil
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  The bioavailability of three altretamine formulations.

Authors:  E A Runhaar; J P Neijt; J J Holthuis; D de Vos
Journal:  Pharm Weekbl Sci       Date:  1989-12-15

5.  The comparative pharmacokinetics of pentamethylmelamine in man, rat, and mouse.

Authors:  C J Rutty; D R Newell; J R Muindi; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 6.  Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy.

Authors:  C R Lee; D Faulds
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

Review 7.  N-methyl antitumour agents. A distinct class of anticancer drugs?

Authors:  D Newell; A Gescher; S Harland; D Ross; C Rutty
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

8.  Distribution, metabolism, and irreversible binding of hexamethylmelamine in mice bearing ovarian carcinoma.

Authors:  E Garattini; T Colombo; M G Donelli; P Catalani; M Bianchi; M D'Incalci; C Pantarotto
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

9.  Pharmacokinetics and metabolism of hexamethylmelamine in mice bearing renal cell tumors.

Authors:  J Dubois; G Atassi; M Hanocq; F Abikhalil
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

10.  Effect of a hepatic activation system on the antiproliferative activity of hexamethylmelamine against human tumor cell lines.

Authors:  K J Miller; R M McGovern; M M Ames
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.